UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

The Lancet (British edition), 2013-03, Vol.381 (9868), p.735-743

2013

Volltextzugriff (PDF)

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Clinical infectious diseases, 2015-08, Vol.61 (3), p.403-408

2015

Volltextzugriff (PDF)

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

AIDS (London), 2011-06, Vol.25 (10), p.1271-1280

2011

Volltextzugriff (PDF)

Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study

PloS one, 2020-08, Vol.15 (8), p.e0237739-e0237739

2020

Volltextzugriff (PDF)

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018

BMC infectious diseases, 2022-04, Vol.22 (1), p.379-379, Article 379

2022

Volltextzugriff (PDF)

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144

Viruses, 2023-06, Vol.15 (6), p.1350

2023

Volltextzugriff (PDF)

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption

PloS one, 2019-01, Vol.14 (1), p.e0210965-e0210965

2019

Volltextzugriff (PDF)

Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients

Journal of clinical medicine, 2021-08, Vol.10 (16), p.3456

2021

Volltextzugriff (PDF)

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

Neurology, 2014-07, Vol.83 (2), p.134-141

2014

Volltextzugriff (PDF)

Short-term Neuropsychiatric and Body Weight Changes in Patients Switching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69)

Current HIV research, 2022-01, Vol.20 (3), p.251-254

2022

Volltextzugriff (PDF)

HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation

Frontiers in immunology, 2018-07, Vol.9, p.1673-1673

2018

Volltextzugriff (PDF)

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e001664

2021

Volltextzugriff (PDF)

Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up

HIV research & clinical practice, 2019-11, Vol.20 (6), p.151-155

2019

Volltextzugriff (PDF)

Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression

AIDS research and human retroviruses, 2014-10, Vol.30 (10), p.984-987

2014

Volltextzugriff (PDF)

Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV

Expert review of anti-infective therapy, 2017-03, Vol.15 (3), p.195-209

2017

Volltextzugriff (PDF)

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

PloS one, 2017-02, Vol.12 (2), p.e0172184-e0172184

2017

Volltextzugriff (PDF)

Switching strategies in the recent era of antiretroviral therapy

Expert review of clinical pharmacology, 2019-03, Vol.12 (3), p.235-247

2019

Volltextzugriff (PDF)

Lack of benefit with omega-3 fatty acid supplementation in HIV patients: A randomized pilot study

HIV research & clinical practice, 2019-05, Vol.20 (3), p.99-105

2019

Volltextzugriff (PDF)

Switch strategies in 2014

BMC infectious diseases, 2014-05, Vol.14 (S2), p.S4-S4, Article S4

Podzamczer, Daniel

2014

Volltextzugriff (PDF)

Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapine

AIDS reviews, 2013-10, Vol.15 (4), p.195-203

Podzamczer, Daniel

2013

Volltextzugriff (PDF)

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

The Lancet (British edition), 2017-11, Vol.390 (10107), p.2063-2072

2017

Volltextzugriff (PDF)

1 – 25 von 313

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(290)
Mit Volltextzugriff
(240)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption

Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

Short-term Neuropsychiatric and Body Weight Changes in Patients Switching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69)

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up

Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression

Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

Switching strategies in the recent era of antiretroviral therapy

Lack of benefit with omega-3 fatty acid supplementation in HIV patients: A randomized pilot study

Switch strategies in 2014

Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapine

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Suchergebnisse filtern